Unicycive Therapeutics, Inc.
- UNCY
- NASDAQ
- Biotechnology
- Kidney Disease Therapeutics
- Biotech (Renal)
$3.52
Today +4.61%Quote Oct 19, 2026, 08:00 PM UTC
−29.56%over the last month
Max drawdown −32.3%From 1-month high −32.3%3 months −38.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
21
Founded
2016
Market value
$96.3M
Quote Oct 19
Analyst target
$22.00
+525.9% from here
Floor
$3.23
8.1% below price
Resistance
$3.74
6.3% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about UNCYPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free